Nurix Therapeutics (NRIX) Revenue & Revenue Breakdown
Nurix Therapeutics Revenue Highlights
Latest Revenue (Y)
$54.55M
Latest Revenue (Q)
$18.45M
Main Segment (Y)
Collaboration Revenue
Nurix Therapeutics Revenue by Period
Nurix Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-11-30 | $54.55M | -29.15% |
| 2023-11-30 | $76.99M | 99.31% |
| 2022-11-30 | $38.63M | 29.84% |
| 2021-11-30 | $29.75M | 66.95% |
| 2020-11-30 | $17.82M | -42.73% |
| 2019-11-30 | $31.11M | -16.91% |
| 2018-11-30 | $37.45M | - |
Nurix Therapeutics generated $54.55M in revenue during NA 2024, up -29.15% compared to the previous quarter, and up 175.31% compared to the same period a year ago.
Nurix Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-02-28 | $18.45M | 38.91% |
| 2024-11-30 | $13.28M | 5.53% |
| 2024-08-31 | $12.59M | 4.10% |
| 2024-05-31 | $12.09M | -27.09% |
| 2024-02-29 | $16.59M | 9.41% |
| 2023-11-30 | $15.16M | -17.91% |
| 2023-08-31 | $18.47M | -39.80% |
| 2023-05-31 | $30.68M | 141.83% |
| 2023-02-28 | $12.69M | 87.01% |
| 2022-11-30 | $6.78M | -37.14% |
| 2022-08-31 | $10.79M | -5.61% |
| 2022-05-31 | $11.43M | 18.82% |
| 2022-02-28 | $9.62M | 30.08% |
| 2021-11-30 | $7.40M | -27.86% |
| 2021-08-31 | $10.25M | 44.58% |
| 2021-05-31 | $7.09M | 41.51% |
| 2021-02-28 | $5.01M | -25.09% |
| 2020-11-30 | $6.69M | 63.75% |
| 2020-08-31 | $4.08M | -2.32% |
| 2020-05-31 | $4.18M | 46.02% |
| 2020-02-29 | $2.86M | 53.81% |
| 2019-11-30 | $1.86M | -82.40% |
| 2019-08-31 | $10.58M | 12.09% |
| 2019-05-31 | $9.44M | 2.22% |
| 2019-02-28 | $9.23M | - |
Nurix Therapeutics generated $18.45M in revenue during Q1 2025, up 38.91% compared to the previous quarter, and up 121.73% compared to the same period a year ago.
Nurix Therapeutics Revenue Breakdown
Nurix Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Nov 24 | Nov 23 |
|---|---|---|
| Collaboration Revenue | $54.55M | $56.99M |
| License Revenue | - | $20.00M |
Latest
Nurix Therapeutics's latest annual revenue breakdown by segment (product or service), as of Nov 24: Collaboration Revenue (100.00%).
Quarterly Revenue by Product
| Product/Service | Nov 24 | Aug 24 | May 24 | Nov 23 | Aug 23 | May 23 |
|---|---|---|---|---|---|---|
| Collaboration Revenue | $29.87M | $12.59M | $12.09M | $27.84M | $18.47M | $10.68M |
| License Revenue | - | - | - | - | - | - |
Latest
Nurix Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Nov 24: Collaboration Revenue (100.00%).
Nurix Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARVN | Arvinas | $263.40M | $102.40M |
| GLUE | Monte Rosa Therapeutics | $75.62M | $4.70M |
| NRIX | Nurix Therapeutics | $54.55M | $18.45M |
| KYMR | Kymera Therapeutics | $47.07M | $3.74M |
| STOK | Stoke Therapeutics | $36.55M | $4.89M |
| FHTX | Foghorn Therapeutics | $22.60M | $7.81M |
| CCCC | C4 Therapeutics | $20.76M | - |
| GBIO | Generation Bio | $19.89M | $4.09M |
| RLAY | Relay Therapeutics | $10.01M | - |
| STTK | Shattuck Labs | $5.72M | $1.61M |
| BDTX | Black Diamond Therapeutics | - | - |
| PRLD | Prelude Therapeutics | - | - |
| SANA | Sana Bio | - | - |
| NKTX | Nkarta | - | - |
| PLRX | Pliant Therapeutics | - | - |
| LYEL | Lyell Immunopharma | - | $34.00K |